In another phase 1b study of the combination of the MET inhibitors savolitinib and gefitinib, up to 52% of patients with EGFR TKI-resistant NSCLC with MET gene amplification had an objective response to the combination treatment regimen (182). This evidence concerns the gene EGFR and non-small cell lung carcinoma.